GlassScriptPhysician profile
April Phares
NPI 1508410754
$8,079.72
in general payments reported to CMS, 2019-2025
48 companies · $4,129 in 2025
The $4,129 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $305 · 2022: $80.75 · 2023: $331 · 2024: $3,233 · 2025: $4,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,686 · Education: $7.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,686.17 |
| Education | $7.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,121.53 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $712.62 | 2023-2025 | Krystexxa, Otezla, Repatha |
| Abbvie INC. | $685.33 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $609.66 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $515.85 | 2023-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $432.66 | 2024-2025 | |
| Lilly USA, LLC | $380.60 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $358.32 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $319.66 | 2024-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $310.08 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $278.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.67 | 2021-2025 | Jardiance, Tradjenta |
| Astellas Pharma US INC | $165.63 | 2024-2025 | Veozah |
| Gilead Sciences, INC. | $152.53 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.20 | 2024-2025 | Caplyta |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $118.67 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $107.03 | 2024-2025 | Ingrezza |
| Phathom Pharmaceuticals, INC. | $106.24 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $103.55 | 2024-2025 | Glassia, Trintellix |
| Mannkind Corporation | $96.72 | 2024-2025 | |
| Exact Sciences Corporation | $92.03 | 2024-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $87.88 | 2025 | Zoryve |
| Lundbeck LLC | $71.70 | 2024-2025 | Vyepti, Rexulti |
| Corcept Therapeutics | $69.76 | 2023-2025 | Korlym |
| Endo USA, INC. | $65.21 | 2024-2025 | Aveed, Xiaflex |
| Verona Pharma, INC. | $63.00 | 2025 | Ohtuvayre |
| Preventric Diagnostics, INC. | $56.65 | 2021 | |
| Dexcom, INC. | $55.69 | 2024 | Dexcom G6 Transmitter |
| Corium, LLC | $52.48 | 2024 | Azstarys |
| Sumitomo Pharma America, INC. | $50.35 | 2025 | Gemtesa |
| Organon LLC | $48.39 | 2024-2025 | Nexplanon |
| Cequr Corporation | $40.71 | 2023-2024 | Cequr Simplicity |
| Impel Pharmaceuticals LLC | $35.39 | 2025 | Trudhesa |
| Mylan Specialty L.P. | $32.62 | 2024 | Yupelri |
| Tris Pharma INC | $32.15 | 2025 | Dyanavel Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.65 | 2023-2024 | Xifaxan |
| Viatris Specialty LLC | $26.54 | 2025 | Yupelri |
| Sequel Med Tech, LLC | $22.46 | 2025 | Twiist |
| Endo Pharmaceuticals INC. | $22.24 | 2024 | Aveed |
| Idorsia Pharmaceuticals US INC | $22.10 | 2023 | Quviviq |
| Renalytix Ai, INC. | $21.41 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Xeris Pharmaceuticals, INC. | $20.87 | 2024 | Gvoke Hypopen |
| Bausch Health US, LLC | $20.43 | 2025 | Wellbutrin, Aplenzin |
| Teva Pharmaceuticals USA, INC. | $20.04 | 2025 | Ajovy |
| Aimmune Therapeutics, INC. | $19.77 | 2024 | |
| Irhythm Technologies, INC. | $15.48 | 2024 | Zio Monitor, Zio Xt Patch |
| Nestle Healthcare Nutrition INC. | $14.87 | 2021 | |
| Akcea Therapeutics, INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Phares listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.